Poland· PL-100459671
Epilantin
A medicinal product containing lacosamidum, registered in Poland by Przedsiębiorstwo Produkcji Farmaceutycznej HASCO-LEK S.A..
Checked against URPL (Poland) on
Informational only — not a medical device.
The record
At a glance
URPL (Poland)- Active substance
- Lacosamidum
- Manufacturer
- Przedsiębiorstwo Produkcji Farmaceutycznej HASCO-LEK S.A.
- Country
- Poland (PL)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 3
1 priced- gtin0590999149461256 szt.PLN 153.07
- gtin05909991494599
- gtin05909991494605
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Lacosamidum in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaARKVIMMANeuraxpharm Bohemia s.r.o., Praha
- SpainBALMID 200 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGIntas Third Party Sales 2005 S.L.
- United StateslacosamideGlenmark Pharmaceuticals Inc. USA
- ItalyLACOSAMIDE ACCORDACCORD HEALTHCARE SLU
- SwitzerlandLacosamid Desitin
- SwedenLacosamide 1A Farma 200 mg Filmdragerad tablett1A Farma A/S
- NetherlandsCosim 200 mg filmomhulde tablettenGedeon Richter Plc.
- FranceLACOSAMIDE ACCORD 200 mg, comprimé pelliculéACCORD HEALTHCARE (ESPAGNE)
Authorised across Europe · EMA
The same active substance is authorised in 30 EEA countries. Names it is sold under:
- Austria · Lacopat, Lacopat Packung Zur Behandlungseinleitung
- Belgium · Lacosamid Hikma, Lacosamide Eg
- Bulgaria · Канилад, Лакозамид Гриндекс
- Cyprus · Kanilad, Lacosadel
- Czechia · Arkvimma, Kanilad
- Germany · Kanilad, Lackepila
- Denmark · 200 mg, Lacosamid Opko Health Spain
- Estonia · Kanilad, Lacosamide Alembic
- Spain · Balmid, Kanilad
- Finland · Lacosamide Fresenius Kabi, Lacosamide Grindeks
- France · Lacosamide Arrow, Lacosamide Biogaran
- United Kingdom (Northern Ireland) · Lacosamide, Lacosamide Amarox
- Greece · Anlamyl, Josamec
- Croatia · Kanilad, Lacosamide Grindeks
- Hungary · Anlamyl, Arkvimma
- Ireland · Lacosamide Ascend, Lacosamide Fresenius Kabi
- Iceland · Josamec, Lacosamide Accord
- Italy · Lacosamide Aurobindo, Lacosamide Doc
- Liechtenstein · Lacosamid Fresenius Kabi, Lacosamide Accord
- Lithuania · Lacosamide Fresenius Kabi, Lacosamide Grindeks
- Luxembourg · Lacosamide Eg
- Latvia · Kanilad, Lacosamide Fresenius Kabi
- Malta · Anlamyl, Kanilad
- Netherlands · Cosim, Lacosamide Amarox
- Norway · Lacosamide Accord, Lacosamide Fresenius Kabi
- Portugal · Lacosamida Alter, Lacosamida Aristo
- Romania · Lacosamidă Teva
- Sweden · Lacomed, Lacosamide 1a Farma
- Slovenia · Lacosabil, Lacosamide Grindeks
- Slovakia · Arkvimma, Kanilad
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/daa23562-101c-443c-84e8-967f576d2fe8 GET /v1/drugs/daa23562-101c-443c-84e8-967f576d2fe8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "200 mg",
"packaging": "05909991494599 ¦ Rp ¦ 146609\n14 tabl.\n05909991494605 ¦ Rp ¦ 146610\n28 tabl.\n05909991494612 ¦ Rp ¦ 146611\n56 tabl.",
"substance": null,
"common_name": "Lacosamidum",
"pl_product_id": "100459671",
"pozwolenie_nr": "27311",
"auth_procedure": "NAR",
"authorisation_validity": "2027-08-31"
}See everything about lacosamidum.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.